HC Wainwright assumed coverage of the shares of Viridian Therapeutics (NASDAQ:VRDN – get grade) In a research note issued to investors on Thursday, The fly reports. The company has set a “buy” rating on the stock. Other stock research analysts have also published research reports on the company. Evercore ISI increased its price target on … Read more
Genmab A/S Shares (NASDAQ:GMAB – get grade) have received a “Hold” consensus recommendation from the sixteen rating firms that currently cover the firm, MercadoBeat.com reports. Two investment analysts rated the stock with a sell recommendation, nine gave a hold recommendation and three assigned a buy recommendation to the company. The twelve-month average price target among … Read more
Immunovant, Inc. Stock (NASDAQ: IMVT – get grade) have earned a “Moderate Buy” consensus recommendation from the seven research firms that currently cover the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts who … Read more
Alvotech (NYSE: ALVO – get grade) – Northland Capmk stock researchers lowered their fiscal 2026 earnings-per-share estimates for Alvotech shares in a research note issued to investors on Thursday, November 17. Northland Capmk analyst C. Byrnes now expects the company to post earnings of $2.10 per share for the year, down from his previous estimate … Read more
Exelixis, Inc. (NASDAQ:EXEL – get grade) executive vice-president Jeffrey Hessekiel sold 18,000 shares of Exelixis in a transaction on Tuesday, May 17. The shares sold at an average price of $25.39, for a total value of $457,020.00. Following the completion of the sale, the Executive Vice President now directly owns 604,822 shares of the company, … Read more
Viridian Therapeutics, Inc. (NASDAQ:VRDN – get grade) – Investment analysts at B. Riley boosted their fiscal 2022 earnings estimates for Viridian Therapeutics in a research note issued Monday, Nov. 14. B. Riley analyst K. Patel now forecasts the company to post earnings per share of ($3.72) for the year, up from his previous estimate of … Read more
Genmab A/S (NASDAQ:GMAB – get grade)’s share price hit a new 52-week high during trading on Wednesday after Cowen raised his price target on the shares to $43.00. The stock traded as high as $43.62 and the last time it traded was $43.19, with volume of 4121 shares. The stock had previously closed at $43.10. … Read more
Veracyte, Inc. (NASDAQ:VCYT – get rating) Director Evan/ Fa Jones sold 6,000 shares of the company in a transaction on Friday, November 11. The shares sold at an average price of $30.23, for a total value of $181,380.00. Following the sale, the director now owns 52,451 shares of the company, valued at $1,585,593.73. The transaction … Read more
Viridian Therapeutics (NASDAQ:VRDN – get rating) JMP Securities stock researchers lowered their price target from $47.00 to $46.00 in a report issued Tuesday, Benzinga reports. The company currently has an “outperform” rating on the stock. JMP Securities’ price target would indicate a potential 126.38% upside from the company’s previous close. Several other research analysts have … Read more
Root Sciences (NASDAQ:ROIV – get rating) SVB Leerink stock research analysts raised their price target from $7.00 to $8.00 in a research note issued on Tuesday, Benzinga reports. The company currently has an “outperform” rating on the stock. SVB Leerink’s price target points to a potential 51.23% rise from the company’s previous close. Several other … Read more